Optimal tunneling method for PICC placement

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective randomized trial compares one-needle versus two-needle tunneling methods used during tunneled PICC catheter placement. Adults aged 18–75 undergoing their first tunneled PICC with a 4Fr single-lumen catheter are randomized to either technique. The goal is to determine which method minimizes catheter-related complications while maintaining safety. The study is conducted at Sun Yat-sen University Cancer Center in Guangzhou and is led by Sun Yat-sen University with no listed collaborators. Participants must meet specific health and consent criteria and will receive standard PICC care and follow-up.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Aged between 18 and 75 years old;
* Educational level of primary school or above, with basic listening, speaking, reading and writing abilities, and capable of completing the questionnaire independently;
* Receiving tunneled PICC catheterization for the first time, with 4Fr single-lumen solo PICC catheter indwelling;
* Able to attend regular PICC maintenance at our hospital as scheduled after catheterization;
* Voluntarily participate in this study and sign the informed consent form for this study as well as the informed consent form for PICC catheterization.

Exclusion Criteria:

* Patients with coagulation dysfunction (INR \> 1.5 / PLT \< 50×10⁹/L);
* Pregnant or lactating women;
* Patients with BMI \< 18.5 kg/m²;
* Patients receiving PICC catheterization via lower extremity veins;
* Patients with known or suspected allergy to components of PICC catheters.

Where it's running

• Sun Yat-sen University Cancer Center
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Study coordinator: Zeyin Hu
• Email: huzy@sysucc.org.cn
• Phone: 15899954190

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Anatomic vs nonanatomic liver resection after conversion therapy for liver cancer

  This study tests whether removing more precisely targeted liver tissue (anatomic resection) works better than removing tissue more broadly (nonanatomic) for patients whose unresectable liver cancer became eligible for surgery after PD-1/PD-L1–based therapy.

  Recruiting Sun Yat-sen University · Guangzhou, Guangdong · NCT07927452

• AI-assisted imaging for diagnosing and managing focal liver lesions

  Researchers are testing whether AI-powered imaging can help doctors better diagnose focal liver lesions in adults undergoing CT scans.

  Recruiting at 2 sites Sun Yat-sen University · Guangzhou, Guangdong and 1 other locations · NCT07926672

• HR20013 for preventing nausea and vomiting in cancer patients receiving chemotherapy

  This real-world study tests whether HR20013 helps prevent nausea and vomiting in adults with cancer who are getting chemotherapy.

  Recruiting Sun Yat-sen University · Guangzhou, Guangdong · NCT07874308

• Anlotinib Plus PD-1 Inhibitor vs PD-1 Inhibitor Alone After Chemoimmunotherapy in Advanced ESCC

  This trial tests whether adding anlotinib to PD-1 inhibitor maintenance after initial chemoimmunotherapy helps people with advanced esophageal squamous cell carcinoma live longer without the cancer growing.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07863141

• Cryoablation with liver-directed immunotherapy and targeted therapy for melanoma liver metastases

  This trial tests a combination therapy including cryoablation, hepatic artery delivery of QL1706, intravenous dacarbazine, and oral lenvatinib to treat liver metastases from malignant melanoma in adults.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07847359

• HAIC plus QL1706 and bevacizumab as first-line therapy for unresectable HER2-negative intrahepatic cholangiocarcinoma

  This study tests a liver-directed chemotherapy plus immune therapy and a blood vessel blocker to see if it helps people with unresectable intrahepatic cholangiocarcinoma.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07841574

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.